Oncotarget

Research Perspectives:

Intraventricular immunovirotherapy; a translational step forward

Joshua D. Bernstock _, Sarah Blitz, Kyung-Don Kang and Gregory K. Friedman _

PDF  |  Full Text  |  How to cite  |  Press Release

Oncotarget. 2023; 14:40-43. https://doi.org/10.18632/oncotarget.28343

Metrics: PDF 232 views  |   Full Text 983 views  |   ?  


Abstract

Joshua D. Bernstock1,2,*, Sarah Blitz1,*, Kyung-Don Kang3 and Gregory K. Friedman3

1 Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA

2 David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

3 Department of Pediatrics, Division of Pediatric Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL 35233, USA

* These authors contributed equally to this work

Correspondence to:

Joshua D. Bernstock, email: [email protected]
Gregory K. Friedman, email: [email protected]

Keywords: oncolytic virotherapy; herpes simplex virus (HSV); G207; intraventricular therapy; leptomeningeal disease

Received: December 19, 2022     Accepted: December 23, 2022     Published: January 12, 2023

Copyright: © 2023 Bernstock et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Oncolytic virotherapy with intratumoral engineered type-1 herpes simplex virus (HSV) has been proven safe with promising efficacy in recent clinical trials for treatment of both pediatric and adult high-grade glioma. However, this approach excludes patients with tumors in surgically inaccessible and/or eloquent brain regions. Current delivery methods are also unable to access/treat those patients with metastatic disease in the spinal cord and/or leptomeningeal disease. A recent preclinical study has paved the way for clinical translation of intraventricular administration of oHSV by identifying and mitigating the toxicity associated with this route for therapeutic benefit in murine models of disseminated medulloblastoma. This work may ultimately allow for targeting of intractable disease and provides a feasible option for the repetitive dosing of clinically relevant immunovirotherapy, G207.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 28343